Lacosamide: a review of its use as adjunctive therapy in the management of partial-onset seizures.

abstract：:At the beginning of the AIDS pandemic, affective disorders (such as depressed mood) were seen in a considerable number of HIV-1-infected individuals. These disorders were a result of the poor physical condition of the patients, brain involvement by the virus (e.g. encephalopathy) or a reaction to disadvantageous livin...

journal_title：CNS drugs

authors： Arendt G

更新日期：2006-01-01 00:00:00

abstract：OBJECTIVE:To determine the efficacy and tolerability of zolmitriptan 2.5 mg oral tablet as an acute treatment for menstrual migraine attacks. METHODS:This was a two-phase, multicentre, randomised, double-blind, placebo-controlled, parallel-group outpatient study (Phase I is reported here). The study was conducted at 2...

journal_title：CNS drugs

authors： Tuchman M,Hee A,Emeribe U,Silberstein S

更新日期：2006-01-01 00:00:00

abstract：:Hashimoto's encephalopathy is a term used to describe an encephalopathy of presumed autoimmune origin characterised by high titres of antithyroid peroxidase antibodies. In a similar fashion to autoimmune thyroid disease, Hashimoto's encephalopathy is more common in women than in men. It has been reported in paediatric...

journal_title：CNS drugs

authors： Mocellin R,Walterfang M,Velakoulis D

更新日期：2007-01-01 00:00:00

abstract：:Cognitive dysfunction is a major cause of disability in patients with multiple sclerosis (MS). The prevalence of cognitive dysfunction is estimated at 45 to 65%. Natural history studies suggest that once cognitive dysfunction develops in a patient with MS, it is not likely to remit. Unlike physical disability in MS, c...

journal_title：CNS drugs

authors： Bagert B,Camplair P,Bourdette D

更新日期：2002-01-01 00:00:00

abstract：:Friedreich ataxia (FA) is a progressive genetic neurological disorder associated with degeneration of the dorsal columns, spinocerebellar tracts and other regions of the nervous system. The disorder results from mutations in the gene referred to as FXN. Almost all mutations are expansions of an intronic GAA repeat in ...

journal_title：CNS drugs

authors： Tsou AY,Friedman LS,Wilson RB,Lynch DR

更新日期：2009-01-01 00:00:00

abstract：:It is difficult to determine the relative efficacy of atypical antipsychotics for the treatment of schizophrenia, based on the available literature. The purpose of this article is to review and compare the efficacy of two atypical antipsychotics: olanzapine and ziprasidone.This review focused on randomised trials in w...

journal_title：CNS drugs

authors： Matza LS,Baker TM,Revicki DA

更新日期：2005-01-01 00:00:00

abstract：:There is escalating interest in cell-based therapies to restore lost dopamine inputs in Parkinson's disease. This is based upon the rationale that implanting dopamine progenitors into the striatum can potentially improve dopamine-responsive motor symptoms. A rich body of data describing clinical trials of previous cel...

journal_title：CNS drugs

authors： Henchcliffe C,Sarva H

更新日期：2020-06-01 00:00:00

abstract：:Alzheimer's disease (AD) is frequently associated with neuropsychiatric symptoms (NPS) such as agitation and aggression, especially in the moderate to severe stages of the illness. The limited efficacy and high-risk profiles of current pharmacotherapies for the management of agitation and aggression in AD have driven ...

journal_title：CNS drugs

authors： Liu CS,Chau SA,Ruthirakuhan M,Lanctôt KL,Herrmann N

更新日期：2015-08-01 00:00:00

abstract：:Oral blonanserin (Lonasen) is an atypical antipsychotic agent indicated for use in patients with schizophrenia in Japan and Korea. It is effective in the treatment of patients with schizophrenia, providing short- and long-term efficacy against both the positive and negative symptoms of the disorder in several randomiz...

journal_title：CNS drugs

authors： Deeks ED,Keating GM

更新日期：2010-01-01 00:00:00

abstract：BACKGROUND:Dravet syndrome (DS) is one of the most severe forms of drug-resistant epilepsy and available interventions fail to control seizures in most patients. Cannabidiol (CBD) is the first in a new class of antiepileptic drugs with a distinctive chemical structure and mechanism of action. OBJECTIVE:The aim of this...

journal_title：CNS drugs

authors： Lattanzi S,Brigo F,Trinka E,Zaccara G,Striano P,Del Giovane C,Silvestrini M

更新日期：2020-03-01 00:00:00

abstract：:The anilidopiperidine opioid remifentanil has pharmacodynamic properties similar to all opioids; however, its pharmacokinetic characteristics are unique. Favourable pharmacokinetic properties, minimally altered by extremes of age or renal or hepatic dysfunction, enable easy titration and rapid dissipation of clinical ...

journal_title：CNS drugs

authors： Beers R,Camporesi E

更新日期：2004-01-01 00:00:00

abstract：:Loxapine is a well-established, first-generation antipsychotic agent. Loxapine inhalation powder (Adasuve(®)) was recently approved in the USA and the EU for use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia. Inhaled loxapine is delivered by a hand-held, single-dose, single-use...

journal_title：CNS drugs

authors： Keating GM

更新日期：2013-06-01 00:00:00

abstract：:The issue of antipsychotic treatment during pregnancy is subject to substantial uncertainty and some controversy among healthcare providers, specifically pertaining to second-generation antipsychotics (SGAs) that are subject to a large gap in safety data during pregnancy compared with antidepressants. The amount of sa...

journal_title：CNS drugs

authors： Damkier P,Videbech P

更新日期：2018-04-01 00:00:00

abstract：:The development of an intervention to slow or halt disease progression remains the greatest unmet therapeutic need in Parkinson's disease. Given the number of failures of various novel interventions in disease-modifying clinical trials in combination with the ever-increasing costs and lengthy processes for drug develo...

journal_title：CNS drugs

authors： Athauda D,Foltynie T

更新日期：2018-08-01 00:00:00

abstract：:The neuronal ceroid lipofuscinoses comprise a group of neurodegenerative lysosomal storage disorders caused by mutations in at least 13 different genes and primarily affect the brain and the retina of children or young adults. The disorders are characterized by progressive neurological deterioration with dementia, epi...

journal_title：CNS drugs

authors： Kohlschütter A,Schulz A,Bartsch U,Storch S

更新日期：2019-04-01 00:00:00

abstract：:How a woman responds to sexual cues is highly dependent on a number of distinct, yet related, factors. Researchers have attempted to explain the female sexual response for decades, but no single model reigns supreme. Proper female sexual function relies on the interplay of somatic, psychosocial and neurobiological fac...

journal_title：CNS drugs

authors： Kingsberg SA,Clayton AH,Pfaus JG

更新日期：2015-11-01 00:00:00

abstract：:Alcoholic patients suffer from harmful allostatic neuroplastic changes in the brain causing an acute withdrawal syndrome upon cessation of drinking followed by a protracted abstinence syndrome and an increased risk of relapse to heavy drinking. Benzodiazepines have long been the treatment of choice for detoxifying pat...

journal_title：CNS drugs

authors： Hammond CJ,Niciu MJ,Drew S,Arias AJ

更新日期：2015-04-01 00:00:00

abstract：:Sodium channel blockers have been the mainstay of the pharmacological management of focal and generalised tonic-clonic seizures for more than 70 years. The focus of this paper will be on phenytoin, carbamazepine, lamotrigine, oxcarbazepine, rufinamide, lacosamide and eslicarbazepine acetate. All these antiepileptic dr...

journal_title：CNS drugs

authors： Brodie MJ

更新日期：2017-07-01 00:00:00

abstract：:The pervasive and devastating nature of substance use disorders underlies the need for the continued development of novel pharmacotherapies. We now know that glia play a much greater role in neuronal processes than once believed.  The various types of glial cells (e.g., astrocytes, microglial, oligodendrocytes) partic...

journal_title：CNS drugs

authors： Jones JD

更新日期：2020-07-01 00:00:00

abstract：:Spinal cord injury (SCI) has a number of severe and disabling consequences, including chronic pain, and around 40% of patients develop persistent neuropathic pain. Pain following SCI has a detrimental impact on the patient's quality of life and is a major specific healthcare problem in its own right. Thus far, there i...

journal_title：CNS drugs

authors： Baastrup C,Finnerup NB

更新日期：2008-01-01 00:00:00

abstract：BACKGROUND:Thrombolytic therapy reduces stroke size and disability by reperfusion and salvage of ischaemic penumbra. Emerging evidence suggests that retrieved penumbra may be the site of ongoing inflammatory pathology that includes extensive microglial activation. Microglial activation may be associated with excessive ...

journal_title：CNS drugs

authors： Tobinick E

更新日期：2011-02-01 00:00:00

abstract：:As in all patient populations, epilepsy is common in pregnant women. Consequently, approximately 1 in 200 pregnancies is exposed to antiepileptic drugs (AEDs). Although exposure to AEDs in utero has been associated with an increased risk of major fetal malformations, most women with epilepsy require medication through...

journal_title：CNS drugs

authors： Adab N

更新日期：2006-01-01 00:00:00

abstract：:New formulations of stimulant medications for the treatment of attention-deficit hyperactivity disorder (ADHD) have been an important focus for pharmaceutical industry research and development over the past decade. In this article, we review and assess the therapeutic potential of five new stimulant formulations (one ...

journal_title：CNS drugs

authors： Connor DF,Steingard RJ

更新日期：2004-01-01 00:00:00

abstract：BACKGROUND:Refractory status epilepticus (RSE) is an emergency with high mortality requiring neurointensive care. Treatment paradigms include first-generation antiepileptic drugs (AEDs) and anesthetics. Lacosamide (LCM) is a new AED, holding promise as a potent treatment option for RSE. High-level evidence regarding sa...

journal_title：CNS drugs

authors： Sutter R,Marsch S,Rüegg S

更新日期：2013-04-01 00:00:00

abstract：:This review focuses on current information about luteal phase administration (i.e. typically for the last 2 weeks of the menstrual cycle) of pharmacological agents for the treatment of premenstrual dysphoric disorder (PMDD). Compared with continuous administration, a luteal phase administration regimen reduces the exp...

journal_title：CNS drugs

authors： Freeman EW

更新日期：2004-01-01 00:00:00

abstract：:Numerous in vitro and in vivo experimental animal studies have demonstrated that gangliosides, particularly GMI ganglioside (siagoside), may stimulate or accelerate the repair of peripheral and central nervous system neurons after various types of damage. Clinical studies of GMl in peripheral neuropathies and stroke, ...

journal_title：CNS drugs

authors： Schneider JS

更新日期：1994-03-01 00:00:00

abstract：:For nearly 50 years, antidepressant drugs have been the first-line treatment for various forms of depression. Despite their widespread use, these medications have significant shortcomings, in particular problems of patient compliance due to adverse effects. The introduction of new formulations of existing antidepressa...

journal_title：CNS drugs

authors： Norman TR,Olver JS

更新日期：2004-01-01 00:00:00

abstract：:Nucleoside analogue reverse transcriptase inhibitors (NRTIs), used as part of highly active antiretroviral therapy for the treatment of HIV and AIDS, disrupt neuronal mitochondrial DNA synthesis, resulting in antiretroviral toxic neuropathy (ATN). Acetyl-L-carnitine (ALC) enhances neurotrophic support of sensory neuro...

journal_title：CNS drugs

authors： Youle M

更新日期：2007-01-01 00:00:00

abstract：:The almost ubiquitous sleep disturbances in patients with depression commonly, but not always, subside with the remission of depression. Evidence linking insomnia with the risk of relapses in recurrent depression, as well as suicide, makes optimization of the treatment of insomnia associated with depression a priority...

journal_title：CNS drugs

authors： Jindal RD

更新日期：2009-01-01 00:00:00

abstract：:The basal ganglia and dopaminergic pathways play a central role in hyperkinetic movement disorders. Vesicular monoamine transporter 2 (VMAT2) inhibitors, which deplete dopamine at presynaptic striatal nerve terminals, are a class of drugs that have long been used to treat hyperkinetic movement disorders, but have rece...

journal_title：CNS drugs

authors： Tarakad A,Jimenez-Shahed J

更新日期：2018-12-01 00:00:00